EGFR and non-small cell lung carcinoma: EGFR‐TKIs have demonstrated efficacy in prolonging progression‐free survival (PFS) and overall survival (OS) in NSCLC patients with EGFR mutations, sparing patients from low‐response and high‐toxicity platinum‐based chemotherapy.17, 18